Glactone Pharma: STAT3 interacts with the androgen receptor and is a drug target in enzalutamide resistant prostate cancer
In collaboration with researchers at Vancouver Prostate Centre in Canada, Glactone Pharma has discovered a novel way of enhancing the effects of current prostate cancer treatments. The research,…